Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment

December 15, 2020 By The ASCO Post Staff

Nadia Harbeck, MD, of the University of Munich, discusses the first outcome data from the phase III ADAPT HR+/HER– trial, which combined both static and dynamic biomarkers to optimize the adjuvant therapy approach in patients with intermediate- or high-risk luminal early breast cancer (Abstract GS4-04).

Related Content